Mylan announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for Quinine Sulfate Capsules, the generic version of Mutual Pharmaceutical’s Qualaquin.

Qualaquin is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria (including chloroquine-resistant strains). It inhibits nucleic acid synthesis, protein synthesis, and glycolysis in Plasmodium falciparum and can bind with hemazoin in parasitized erythrocytes.

Quinine Sulfate is available in 324mg dosage strength capsules. Mylan has begun shipping this product.

For more information call (800) RX-MYLAN or visit